专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090258850A1 STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS 审中-公开
标题翻译：稳定的治疗组合物和制剂
公开(公告)号：US20090258850A1
公开(公告)日：2009-10-15
申请号：US12196271
申请日：2008-08-21
申请人： James M. Frincke , Steven K. White , Yu Ge , Weicheng Liaw , Tao Hu
发明人： James M. Frincke , Steven K. White , Yu Ge , Weicheng Liaw , Tao Hu
IPC分类号： A61K31/5685
CPC分类号： A61K9/10 , A61K9/0019
摘要： The invention relates to pharmaceutically acceptable formulations comprising an active pharmaceutical ingredient such as androst-5-ene-3β,17β-diol, androst-5-ene-3β,7β,17β-triol or derivatives of either of these compounds and an air oxidizable excipient that have been stabilized with respect to efficacy. Use of the efficacy-stabilized formulations to treat a number of conditions or symptoms thereof, such as a symptom associated with exposure to radiation is described.
摘要翻译：本发明涉及包含活性药物成分如雄甾-5-烯-3β，17β-二醇，雄甾-5-烯-3β，7beta，17β-三醇或这些化合物的衍生物的药学上可接受的制剂和可氧化的相关功效已被稳定的赋形剂。描述了使用功效稳定的制剂来治疗许多病症或症状，例如与暴露于辐射相关的症状。

2. 发明授权

US07547687B2 Therapeutic treatment methods 失效
公开(公告)号：US07547687B2
公开(公告)日：2009-06-16
申请号：US11674128
申请日：2007-02-12
申请人： Christopher L. Reading , Clarence N. Ahlem , Dominick L. Auci , Charles Dowding , James M. Frincke , Mei Li , Theodore M. Page , Dwight R. Stickney , Richard J. Trauger , Steven K. White
发明人： Christopher L. Reading , Clarence N. Ahlem , Dominick L. Auci , Charles Dowding , James M. Frincke , Mei Li , Theodore M. Page , Dwight R. Stickney , Richard J. Trauger , Steven K. White
IPC分类号： A61K31/568
CPC分类号： A61K31/56 , A61K31/58
摘要： The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

3. 发明申请

US20080090791A1 Cystic fibrosis treatment methods 失效
标题翻译：囊性纤维化治疗方法
公开(公告)号：US20080090791A1
公开(公告)日：2008-04-17
申请号：US11549580
申请日：2006-10-13
申请人： Christopher L. Reading , Clarence N. Ahlem , Dominick L. Auci , Charles Dowding , James M. Frincke , Mei Li , Theodore Page , Dwight R. Stickney , Richard J. Trauger , Steven K. White
发明人： Christopher L. Reading , Clarence N. Ahlem , Dominick L. Auci , Charles Dowding , James M. Frincke , Mei Li , Theodore Page , Dwight R. Stickney , Richard J. Trauger , Steven K. White
IPC分类号： A61K31/58 , A61K31/56 , A61P43/00
CPC分类号： A61K31/58 , A61K31/56 , Y02A50/411
摘要： The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性白细胞减少症或其他示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

4. 发明申请

US20080085873A1 Disease treatment methods 审中-公开
标题翻译：疾病治疗方法
公开(公告)号：US20080085873A1
公开(公告)日：2008-04-10
申请号：US11549615
申请日：2006-10-13
申请人： Christopher L. Reading , Clarence N. Ahlem , Dominick L. Auci , Charles Dowding , James M. Frincke , Mei Li , Theodore M. Page , Dwight R. Stickney , Richard J. Trauger , Steven K. White
发明人： Christopher L. Reading , Clarence N. Ahlem , Dominick L. Auci , Charles Dowding , James M. Frincke , Mei Li , Theodore M. Page , Dwight R. Stickney , Richard J. Trauger , Steven K. White
IPC分类号： A61K31/58 , A61P17/06 , A61P3/10 , A61P43/00
CPC分类号： A61K31/58 , A61K31/56 , Y02A50/411
摘要： The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α, 17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性粒细胞减少症或其它示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

5. 发明授权

US07482334B2 Therapeutic treatment methods 有权
标题翻译：治疗方法
公开(公告)号：US07482334B2
公开(公告)日：2009-01-27
申请号：US11674126
申请日：2007-02-12
申请人： James M. Frincke , Steven K. White
发明人： James M. Frincke , Steven K. White
IPC分类号： A61K31/5685 , A61K31/569 , A61K31/567
CPC分类号： A61K31/56 , A61K31/58
摘要： The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性粒细胞减少症或其它示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

6. 发明申请

US20130066087A1 METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 有权
标题翻译：制备17-烷基-7-羟基甾体和相关化合物-2的方法
公开(公告)号：US20130066087A1
公开(公告)日：2013-03-14
申请号：US13664304
申请日：2012-10-30
申请人： Steven K. White , Yu Ge , Yujin Huang
发明人： Steven K. White , Yu Ge , Yujin Huang
IPC分类号： C07J75/00
CPC分类号： C07J1/0048 , C07J71/00 , C07J75/00
摘要： The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.
摘要翻译：本发明涉及制备17-炔基-7-羟基甾族化合物的方法，例如17-乙炔基-10R，13S-二甲基2,3,4,7,8R，9S，10,11,12,13,14S， 15,16,17-十六氢-1H-环戊二烯并[a]菲-3R，7R，17S-三醇（也称为17α-乙炔基 - 雄甾-5-烯-3＆bgr，7＆bgr，17＆bgr三醇）其基本上不含在核雌激素受体上具有结合活性的工艺杂质。

7. 发明授权

US09163059B2 Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds-2 有权
标题翻译：制备17-炔基-7-羟基类固醇及相关化合物的方法2
公开(公告)号：US09163059B2
公开(公告)日：2015-10-20
申请号：US13664304
申请日：2012-10-30
申请人： Steven K. White , Yu Ge , Yujin Huang
发明人： Steven K. White , Yu Ge , Yujin Huang
IPC分类号： C07J71/00
CPC分类号： C07J1/0048 , C07J71/00 , C07J75/00
摘要： The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.
摘要翻译：本发明涉及制备17-炔基-7-羟基甾族化合物的方法，例如17-乙炔基-10R，13S-二甲基2,3,4,7,8R，9S，10,11,12,13,14S， 15,16,17-十六氢-1H-环戊二烯并[a]菲-3R，7R，17S-三醇（也称为17α-乙炔基 - 雄甾-5-烯-3＆bgr，7＆bgr，17＆bgr三醇）其基本上不含在核雌激素受体上具有结合活性的工艺杂质。

8. 发明授权

US08309746B2 Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds 有权
标题翻译：制备17-炔基-7-羟基类固醇及相关化合物的方法
公开(公告)号：US08309746B2
公开(公告)日：2012-11-13
申请号：US12479626
申请日：2009-06-05
申请人： Steven K. White , Yu Ge , Yujin Huang
发明人： Steven K. White , Yu Ge , Yujin Huang
IPC分类号： C07J1/00
CPC分类号： C07J1/0048 , C07J71/00 , C07J75/00
摘要： The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.
摘要翻译：本发明涉及制备17-炔基-7-羟基甾族化合物的方法，例如17-乙炔基-10R，13S-二甲基2,3,4,7,8R，9S，10,11,12,13,14S， 15,16,17-十六氢-1H-环戊二烯并[a]菲-3R，7R，17S-三醇（也称为17α-乙炔基 - 雄甾-5-烯-3＆bgr，7＆bgr，17＆bgr三醇）其基本上不含在核雌激素受体上具有结合活性的工艺杂质。

9. 发明申请

US20120214987A1 METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS 审中-公开
标题翻译：制备3ALPHA-氧气取代的甾体的方法和化合物
公开(公告)号：US20120214987A1
公开(公告)日：2012-08-23
申请号：US13327701
申请日：2011-12-15
申请人： Yu Ge , Steven K. White , Yujin Huang
发明人： Yu Ge , Steven K. White , Yujin Huang
IPC分类号： C07J71/00 , C07J3/00
CPC分类号： C07J11/00 , C07J1/0011 , C07J1/0022 , C07J1/0025 , C07J1/0048 , C07J21/003 , C07J41/0038 , C07J51/00 , C07J71/001
摘要： The invention relates to processes for preparing 3α-O-linked steroids including 3α-O-linked-androst-5-ene steroids and 3α-O-linked-5a-androstane steroids. In one process a 3α,4α-epoxy androst-5-en-17-one is predominately reduced at the epoxy moiety wherein reduction of the 3α,4α epoxy functional group occurs preferentially at position C4 with retention of configuration at position C3 to provide a 3α-O-linked-androst-5-ene steroid. In another process, conditions are provided for inversion of configuration of a 3β-hydroxy-androst-5-ene steroid by the Mitsunobu reaction to provide a 3α-O-linked-androst-5-ene steroid with reduced amounts of 3α,5α-cycloandrostane side-product impurities.
摘要翻译：本发明涉及制备包括3α-O-连接的雄甾-5-烯类固醇和3α-O-连接的-5α-雄甾烷类固醇的3α-O-连接的类固醇的方法。在一个方法中，3α，4α-环氧雄甾-5-烯-17-酮在环氧部分主要降低，其中3α，4α环氧官能团的还原优先在位置C4处发生，并保留C3位置上的构型，以提供 3α-O-连接 - 雄甾-5-烯类固醇。在另一种方法中，通过Mitsunobu反应提供3β-羟基 - 雄甾-5-烯类固醇的构型的反转条件，以提供3α-5连接的雄甾-5-烯类固醇，减少量的3α，5α - 环二雄甾烷副产物杂质。

10. 发明申请

US20090326251A1 METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS 有权
标题翻译：制备17-烷基-7-羟基甾体和相关化合物的方法
公开(公告)号：US20090326251A1
公开(公告)日：2009-12-31
申请号：US12479626
申请日：2009-06-05
申请人： Steven K. White , Yu Ge , Yujin Huang
发明人： Steven K. White , Yu Ge , Yujin Huang
IPC分类号： C07J1/00
CPC分类号： C07J1/0048 , C07J71/00 , C07J75/00
摘要： The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.
摘要翻译：本发明涉及制备17-炔基-7-羟基甾族化合物的方法，例如17-乙炔基-10R，13S-二甲基2,3,4,7,8R，9S，10,11,12,13,14S， 15,16,17-十六氢-1H-环戊二烯并[a]菲-3R，7R，17S-三醇（也称为17α-乙炔基 - 雄甾-5-烯-3β，7beta，17β-三醇）没有在核雌激素受体上具有结合活性的工艺杂质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式